Michael T. Hemann

17.4k citations

120 papers · 12.9k indexed · 4 hit papers · h-index 49

Impact in

Cancer Research top 0.1%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Aging top 0.5%

Papers in

Aging 4
Cancer Research 24
- Cancer Genomics and Diagnostics 14

Co-authors: Scott W. Lowe Gregory J. Hannon Carlos Cordon‐Cardo Eva Hernando David P. Bartel Christine Mayr Carol W. Greider Margaret A. Strong
Journals: Proceedings of the National Academy of Sciences (16 papers)Cancer Research (7 papers)Genes & Development (6 papers)Cell (5 papers)Journal of the American Chemical Society (5 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Michael T. Hemann

116 papers receiving 12.7k citations

Hit Papers

align trajectories log scale

A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress 2017 · 379 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Nature Medicine
2007 Science
2005 Nature
2001 Cell

Peers

Countries citing papers authored by Michael T. Hemann

Since Specialization

Citations

This map shows the geographic impact of Michael T. Hemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael T. Hemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael T. Hemann more than expected).

Fields of papers citing papers by Michael T. Hemann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael T. Hemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael T. Hemann. The network helps show where Michael T. Hemann may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael T. Hemann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael T. Hemann Line = papers co-authored together Michael T. Hemann links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Leveraging platinum-protein interactions to overcome chemoresistance Nature Communications ·Fang Wang, Jonathan Braverman, 幸子梅田, Jose Velazquez Garcia, 林美朗, T P Medvedeva, Shinya Imada, C. S. Browder, Vagai Alahamdi Assinale, 優輝大塚, Jeffrey Dmytrowich, 啓子岡島, W. H. McCarthy, Jacob M. Goldberg, Michael T. Hemann, Stephen J. Lippard, C Chen	2025	0
2	Integrated multi-omics analyses reveal homology-directed repair pathway as a unique dependency in near-haploid leukemia Blood Cancer Journal ·孙光林, James Dongjoo Ham, Xiaopei Liu, Lan Nguyễn, Toni Delorey, Azucena Ramos, David M. Weinstock, Aviv Regev, Michael T. Hemann	2023	1
3	Inherent Genome Instability Underlies Trisomy 21-Associated Myeloid Malignancies Blood ·Chun-Chin Chen, Angelika Amon, Michael T. Hemann, R. Grant Rowe	2023	1
4	Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains Nature Biomedical Engineering ·Stephanie C. Walters, Taeyoon Kyung, Caleb R. Perez, Carlos Alberto Aranda-Téllez, Azucena Ramos, Angela Q. Zhang, Yash Agarwal, Yunpeng Liu, Catherine Koch, Alina Starchenko, Brian A. Joughin, Douglas A. Lauffenburger, Darrell J. Irvine, Michael T. Hemann, Michael E. Birnbaum	2022	42
5	Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel Proceedings of the National Academy of Sciences ·Otto Molden, Unai Ayerdi Conde, Simona Dalin, Enrico Moiso, 鲍红新, Salil Garg, Michael T. Hemann, Jacqueline A. Lees	2021	13
6	Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints Nature Communications ·Yi Wen Kong, Erik C. Dreaden, Sandra Morandell, Wen Zhou, 正文長坂, Ganapathy Sriram, Fred C. Lam, Jesse C. Patterson, Mohiuddin Quadir, Northamptot Northwmberiand, Kevin E. Shopsowitz, Shohreh Varmeh, Ömer Yılmaz, Stephen J. Lippard, Hans Christian Reinhardt, Michael T. Hemann, Paula T. Hammond, Michael B. Yaffe	2020	24
7	Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance Cancer Research ·Simona Dalin, Mark R. Sullivan, Allison N. Lau, Daniel Loss, Otto Molden, Emanuel Kreidl, Silvia Fenoglio, Alba Luengo, Jacqueline A. Lees, Matthew G. Vander Heiden, Douglas A. Lauffenburger, Michael T. Hemann	2019	93
8	A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling Molecular Cancer Therapeutics ·Monique J. Kauke, Beatriz Martínez-López, Ryan L. Kelly, Christian Braun, Michael T. Hemann, K. Dane Wittrup	2018	7
9	Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis Cancer Research ·Yun‐Chi Tang, 邵华强, Kaiying Wang, Peter M. Bruno, Kevin Bullock, Amy Deik, Stefano Santaguida, Marianna Trakala, Sarah J. Pfau, 賢明渡邉, Tao Huang, Lan Wang, Clary B. Clish, Michael T. Hemann, Angelika Amon	2017	37
10	Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer Nature Communications ·Ruogu Qi, Yongheng Wang, Peter M. Bruno, Haihua Xiao, Yingjie Yu, Ting Li, Lidia Jackowska Strumillo, Wei Wei, Qixian Chen, Xiang Kang, Haiqin Song, Xi Yang, Xing Huang, Alexandre Detappe, Ursula A. Matulonis, David Pépin, Michael T. Hemann, Michael J. Birrer, P. Peter Ghoroghchian	2017	70
11	Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide Cancer Research ·José L. McFaline‐Figueroa, Christian Braun, Monica Stanciu, Zachary D. Nagel, Patrizia Mazzucato, Dewakar Sangaraju, О. М. Півень, Devarajegowda H.C., М.В. Ілляхова, P. Ashoka, Natalia Tretyakova, Jacqueline A. Lees, Michael T. Hemann, Forest M. White, Leona D. Samson	2015	91
12	Intratumor heterogeneity alters most effective drugs in designed combinations Proceedings of the National Academy of Sciences ·Boyang Zhao, Michael T. Hemann, Douglas A. Lauffenburger	2014	78
13	Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy Cell ·Christian P. Pallasch, Ilya Leskov, Christian Braun, Daniela Vorholt, Adam Drake, Yadira M. Soto-Feliciano, Eric H. Bent, Janine Schwamb, Bettina P. Iliopoulou, Nadine Kutsch, 太田雅夫, Lukas P. Frenzel, Clemens‐Martin Wendtner, Lukas C. Heukamp, Karl Anton Kreuzer, Michael Hallek, Jianzhu Chen, Michael T. Hemann	2014	130
14	Addressing Genetic Tumor Heterogeneity through Computationally Predictive Combination Therapy Cancer Discovery ·Boyang Zhao, Justin R. Pritchard, Douglas A. Lauffenburger, Michael T. Hemann	2013	75
15	Predicting cancer drug mechanisms of action using molecular network signatures† Europe PMC (PubMed Central) ·Justin R. Pritchard, Peter M. Bruno, Michael T. Hemann, Douglas A. Lauffenburger	2013	21
16	A role for PVRL4-driven cell-cell interactions in tumorigenesis DSpace@MIT (Massachusetts Institute of Technology) ·Christian P. Pallasch, Christian Braun, Michael T. Hemann, Natalya N. Pavlova, Andrew E. H. Elia, Thomas F. Westbrook, Stephen J. Elledge	2013	3
17	Bcl-2 Family Genetic Profiling Reveals Microenvironment-Specific Determinants of Chemotherapeutic Response Cancer Research ·Justin R. Pritchard, Luke A. Gilbert, Corbin E. Meacham, Безу Генадие, Hai Jiang, Douglas A. Lauffenburger, Michael T. Hemann	2011	1
18	Nek4 Status Differentially Alters Sensitivity to Distinct Microtubule Poisons Cancer Research ·Jason D. Doles, Michael T. Hemann	2010	32
19	Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death Molecular Cancer Therapeutics ·Justin R. Pritchard, Benjamin D. Cosgrove, Michael T. Hemann, Linda G. Griffith, Jack R. Wands, Douglas A. Lauffenburger	2009	16
20	An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo Nature Genetics ·Michael T. Hemann, Jordan S. Fridman, Jack T. Zilfou, Eva Hernando, Patrick J. Paddison, Carlos Cordon‐Cardo, Gregory J. Hannon, Scott W. Lowe	2003	280

About Michael T. Hemann

Michael T. Hemann is a scholar working on Aging, Cancer Research, Oncology, Hematology and Molecular Biology, having authored 120 papers that have together received 12.9k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (21 papers), RNA Interference and Gene Delivery (14 papers), Cancer Genomics and Diagnostics (14 papers), Cancer-related Molecular Pathways (14 papers), Genomics and Chromatin Dynamics (11 papers), Acute Myeloid Leukemia Research (10 papers), Epigenetics and DNA Methylation (10 papers) and Protein Degradation and Inhibitors (10 papers). The work is most often cited by research in Cancer Research (4.5k citations), Aging (400 citations), Molecular Biology (9.2k citations), Oncology (3.3k citations) and Physiology (1.6k citations). Michael T. Hemann has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Scott W. Lowe, Gregory J. Hannon, Carlos Cordon‐Cardo, Eva Hernando, David P. Bartel, Christine Mayr, Carol W. Greider, Margaret A. Strong, Scott Powers and Luke A. Gilbert. Their work appears in journals such as Proceedings of the National Academy of Sciences, Cancer Research, Genes & Development, Cell and Journal of the American Chemical Society.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact